Zydelig Europska Unija - hrvatski - EMA (European Medicines Agency)

zydelig

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.

Sufentanil Altamedics 5 mikrograma/ml otopina za injekciju/infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

sufentanil altamedics 5 mikrograma/ml otopina za injekciju/infuziju

altamedics d.o.o., vrbani 4, zagreb, hrvatska - sufentanilcitrat - otopina za injekciju / infuziju - 5 mikrograma/ml - urbroj: 1 ml otopine za injekciju/infuziju sadrži 5 mikrograma sufentanila u obliku suflentanilcitrata

Irinotekan Accord 20 mg/ml koncentrat za otopinu za infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

irinotekan accord 20 mg/ml koncentrat za otopinu za infuziju

accord healthcare polska sp. z o.o., ul. tasmowa 7, mazowieckie, varšava, poljska - irinotekanklorid trihidrat - koncentrat za otopinu za infuziju - 20 mg/ml - urbroj: 1 ml koncentrata sadrži 20 mg irinotekanklorid trihidrata, što odgovara 17,33 mg irinotekana

Irinotesin 20 mg/ml koncentrat za otopinu za infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

irinotesin 20 mg/ml koncentrat za otopinu za infuziju

teva b.v., swensweg 5, haarlem, nizozemska - irinotekanklorid trihidrat - koncentrat za otopinu za infuziju - 20 mg/ml - urbroj: jedan ml koncentrata sadrži 20 mg irinotekanklorid trihidrata što odgovara 17,33 mg/ml irinotekana

CAMPTO 100 mg/5 mL koncentrat za rastvor za infuziju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

campto 100 mg/5 ml koncentrat za rastvor za infuziju

pfizer bh d.o.o. sarajevo - irinotekan - koncentrat za rastvor za infuziju - 100 mg/5 ml - 5 ml koncentrata za rastvor za infuziju sadrži: 100 mg irinotekanhidrohlorid, trihidrata

IRINOTECAN KABI 40 mg/2 mL Koncentrat za otopinu za infuziju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

irinotecan kabi 40 mg/2 ml koncentrat za otopinu za infuziju

amicus pharma d.o.o. - irinotekan - koncentrat za otopinu za infuziju - 40 mg/2 ml - 1 ml koncentrata za otopinu za infuziju sadrži: 20 mg irinotekanhidrohlorid, trihidrata (što odgovara 17,33 mg/ml irinotekana).

IRINOTECAN KABI 100 mg/5 mL Koncentrat za otopinu za infuziju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

irinotecan kabi 100 mg/5 ml koncentrat za otopinu za infuziju

amicus pharma d.o.o. - irinotekan - koncentrat za otopinu za infuziju - 100 mg/5 ml - 1 ml koncentrata za otopinu za infuziju sadrži: 20 mg irinotekanhidrohlorid, trihidrata (što odgovara 17,33 mg/ml irinotekana).

Libtayo Europska Unija - hrvatski - EMA (European Medicines Agency)

libtayo

regeneron ireland designated activity company (dac) - cemiplimab - karcinom, squamous cell - antineoplastična sredstva - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Prograf 0,5 mg tvrde kapsule Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

prograf 0,5 mg tvrde kapsule

astellas d.o.o., ilica 1, zagreb, hrvatska - takrolimus hidrat - kapsula, tvrda - 0,5 mg - urbroj: jedna kapsula sadrži 0,5 mg takrolimusa (u obliku hidrata)